MRC Holland

MRC Holland is based in Amsterdam. It was founded by Dr. Jan Schouten in 1985 and initially focused on the production of restriction enzymes and molecular weight markers.

In 1997, the company shifted its focus to the development of new methods of DNA analysis. In 2002, the first article on multiplex ligation-dependent probe amplification, or MLPA®, was published. Since then, MLPA has become the “gold standard” for detecting copy number variations, with over 350 probe mixes available on the market.

MRC Holland continues to innovate in the development of new MLPA assays, the improvement of existing assays, and the recent introduction of two new technologies.

2 items 1 direction

In 2018, the first commercial screening kit for spinal muscular atrophy (SMA) in newborns was introduced. In 2020, digitalMLPA technology was introduced, combining the proven quality of MLPA with the power of NGS technology to analyze a large number of sequences in a single test.

Company products

Molecular genetic diagnostics 2

Brand catalog